Formulation and In-Vitro evaluation of Nanocrystal formulation of poorly soluble drugs
Abstract
Introduction:-Poor solubility of drug compounds which accounts for 40% of new molecules investigated at present is an issue of great concern in pharmaceutical industry and reducing particle size (i,e to reduce below 1000 nm )of drug candidate to be investigated is one of the simplest and efficient ways to overcome this challenge. Drug nanocrystals, solid nanosized drug particles are defined as formulation having 100% drug, which are covered by a stabilizer layer. In this study attempt was made to formulate and evaluate nanocrystals of poorly soluble drugs having low oral bioavailability. Material and method:- Nanocrystals were prepared successfully by varying concentration of different stabilizers by anti-solvent precipitation method. The formulated nanocrystals were evaluated by determining physicochemical characteristics such as physical appearance, Differential Scanning Calorimetry (DSC), scanning electron microscopy (SEM), X-ray powder diffractometry, solubility studies, particle size distribution, zeta potential, and in vitro drug release profile studies. Results:- An in-vitro study was performed on the successful formulation in comparison to drug powder using dissolution apparatus The particle size of RVT and PSNC-3 was found to be 1975.3 nm and 790.1 nm respectively. Conclusion: Precipitated Nanocrystals formulated with different stablizer’s method resultedin formation of small and uniform RVT nanocrystals with an improved saturation solubility, dissolution rate.
Keywords: Nanocrystal, poorly soluble drugs
Keywords:
Nanocrystal, poorly soluble drugsDOI
https://doi.org/10.22270/jddt.v9i4-s.3873References
Huttunen, K.M., Raunio, H., Rautio, J., Prodrugs – from serendipity to rational design. Pharmacol. Rev. 2011; 63:750–771
Serajuddin, A.T., Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 2007; 59:603–616
Seedher, N., Kanojia, M., Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharm. Dev. Technol. 2009; 14:185–192
Bilensoy, E., Hincal, A.T., Revent advances and future directions in amphiphilic cyclodextrin nanoparticles. Expert Opin. Drug Deliv. 2009; 6:1161–1173
Thakuria, R., Delori, A., Jones, W., Lipert, M.P., Roy, L., Rodriguez-Hornedo, N., Pharmaceutical cocrystals and poorly soluble drugs. Int. J. Pharm. 2013; 453:101–125
Babu, N.J., Nangia, A., Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst. Growth Des. 2011; 11:2662–2679.
Tuomela, A., Laaksonen, T., Laru, J., Antikainen, O., Kiesvaara, J., Ilkka, J., Oksala, O., Rönkkö, S., Järvinen, K., Hirvonen, J., Peltonen, L., Solid formulations by a nanocrystal approach: critical process parameters regarding scale-ability of nanocrystals for tableting applications. Int. J. Pharm. 2015; 485:77–86.
Thi, T.D., Van Speybroeck, M., Barillaro, V., Martens, J., Annaert, P., Augustijns, P., Van Humbeeck, J., Vermant, J., Van den Mooter, G., Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. Eur. J. Pharm. Sci. 2009; 38:479–488.
Shakeel, F., Faisal, M.S., Nanoemulsion: a promising tool for solubility and dissolution enhancement of celecoxib. Pharm. Dev. Technol. 2010; 15:53–56.
Porter, C.J.H., Trevaskis, N.L., Charman, W.N., Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. 2007; 6:231–248.
Shakeel, F., Faisal, M.S., Nanoemulsion: a promising tool for solubility and dissolution enhancement of celecoxib. Pharm. Dev. Technol. 2010; 15:53–56.
Chen, H., Khemtong, C., Yang, X., Chang, X., Gao, J., Nanonization stragegies for poorly water-soluble drugs. Drug Discov. Today 2011; 16:354–360
Brough, C., Williams III, R.O., Amorphous solid dispersions and nano-crystaltechnologies for poorly water-soluble drug delivery. Int. J. Pharm. 2013; 453:157–166
Loftsson, T., Brewster, M.E., Pharmaceutical applications of cyclodextrins: basic science and product development. J. Pharm. Pharmacol. 2010; 62:1607–1621
Brouwers, J., Brewster, M.E., Augustijns, P., Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 2009; 98:2549–2572
Liu, P., Rong, X., Laru, J., van Veen, B., Kiesvaara, J., Hirvonen, J., Laaksonen, T., Peltonen, L., Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int. J. Pharm. 2011; 411:215–222.
Borchard, G., 2015. Drug nanocrystals. In: In: Crommelin, D., de Vlieger, J. (Eds.), Non-Biological Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, vol. 20. Springer, Cham, pp. 171–189
Kesisoglou, F., Panmai, S., Wu, Y., Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 2007; 59:631–644
Gao, L., Liu, G.Y., Ma, J.L., Wang, X.Q., Zhou, L., Li, X., Drug nanocrystals: in vivo performances. J. Control. Release 2012; 160:418–430.
Lu, Y., Li, Y., Wu, W., Injected nanocrystals for targeted drug delivery. Acta Pharm. Sin. B 2016; 6:106–113.
R.R. Sevda, A.S. Ravetkar, P.J. Shirote, UV spectrophotometric estimation ofRosuvastatin calcium and fenofibrate in bulk drug and dosage form using simul-taneous equation method, Int. J. Chem. Tech. Res. 2011; 3:629–635..
Fu, Q., Sun, J., Zhang, D., Li, M., Wang, Y., Ling, G., Liu, X., Sun, Y., Sui, X., Luo, C., Sun, L., Han, X., Lian, H., Zhu, M., Wang, S., He, Z., Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. Colloids Surf. B Biointerfaces 2013; 109:161–166.
Oussoren C1, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev. 2001; 50(1-2):143-56.
Published
Abstract Display: 1454 
PDF Downloads: 934 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.